APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

NK Cell Therapy

Cell therapy, a new therapeutic approach that uses a patient's own immune cells to attack tumors, has emerged as one of the most promising breakthroughs in cancer treatment. NK cells are the body's first line of defense against infections and diseases with an innate ability to rapidly seek and destroy abnormal cells.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Cell therapy, a new therapeutic approach that uses a patient's own immune cells to attack tumors, has emerged as one of the most promising breakthroughs in cancer treatment. NK cells are the body's first line of defense against infections and diseases with an innate ability to rapidly seek and destroy abnormal cells.

Selected research

Market Analysis & Forecast

Global NK Cell Therapy Market Analysis and Forecast 2026-2032

Report ID 173916700220 December 2025198 pages

Choose your research edition.

Industry ResearchNK Cell Therapy Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal NK Cell Therapy Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal NK Cell Therapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal NK Cell Therapy Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal NK Cell Therapy Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

Cell therapy, a new therapeutic approach that uses a patient's own immune cells to attack tumors, has emerged as one of the most promising breakthroughs in cancer treatment. NK cells are the body's first line of defense against infections and diseases with an innate ability to rapidly seek and destroy abnormal cells.

North America is the largest NK Cell Therapy market with about 51% market share. Europe is follower, accounting for about 33% market share.The key manufacturers are Nektar Therapeutics, Innate Pharma SA, Affimed, Chipscreen Biosciences, Fate Therapeutics, Glycostem Therapeutics, Dragonfly Therapeutics, Kiadis Pharma, NantWorks, Nkarta Therapeutics, Fortress Biotech etc. Top 3 companies occupied about 82% market share.

Report Includes

Read the full market overview

This report presents an overview of global market for NK Cell Therapy, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of NK Cell Therapy, also provides the revenue of main regions and countries. Of the upcoming market potential for NK Cell Therapy, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the NK Cell Therapy revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global NK Cell Therapy market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for NK Cell Therapy revenue, projected growth trends, production technology, application and end-user industry.

NK Cell Therapy Segment by Company

Nektar Therapeutics

Innate Pharma SA

Affimed

Chipscreen Biosciences

Fate Therapeutics

Glycostem Therapeutics

Dragonfly Therapeutics

Kiadis Pharma

NantWorks

Nkarta Therapeutics

Fortress Biotech

NK Cell Therapy Segment by Type

NK Cell Therapies

NK Cell Directed Antibodies

NK Cell Therapy Segment by Application

Cancer

Gastrointestinal Diseases

Others

NK Cell Therapy Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global NK Cell Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of NK Cell Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of NK Cell Therapy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of NK Cell Therapy in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of NK Cell Therapy company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, NK Cell Therapy revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global NK Cell Therapy Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. NK Cell Therapies Major Player Table 3. NK Cell Directed Antibodies Major Player Table 4. Global NK Cell Therapy Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Cancer Major Player Table 6. Gastrointestinal Diseases Major Player Table 7. Others Major Player Table 8. NK Cell Therapy Industry Trends Table 9. NK Cell Therapy Industry Drivers Table 10. NK Cell Therapy Industry Opportunities and Challenges Table 11. NK Cell Therapy Industry Restraints Table 12. Global NK Cell Therapy Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global NK Cell Therapy Market Size by Region (2021-2026) & (US$ Million) Table 14. Global NK Cell Therapy Market Share by Region (2021-2026) Table 15. Global NK Cell Therapy Market Size by Region (2027-2032) & (US$ Million) Table 16. Global NK Cell Therapy Market Share by Region (2027-2032) Table 17. Global NK Cell Therapy Revenue by Players (US$ Million) & (2021-2026) Table 18. Global NK Cell Therapy Revenue Market Share by Players (2021-2026) Table 19. Global NK Cell Therapy Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global NK Cell Therapy Key Players Headquarters & Area Served Table 21. Global NK Cell Therapy Players, Product Type & Application Table 22. Global NK Cell Therapy Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global NK Cell Therapy by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global NK Cell Therapy Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global NK Cell Therapy Revenue by Type (2021-2026) & (US$ Million) Table 27. Global NK Cell Therapy Revenue by Type (2027-2032) & (US$ Million) Table 28. Global NK Cell Therapy Revenue Market Share by Type (2021-2026) Table 29. Global NK Cell Therapy Revenue Market Share by Type (2027-2032) Table 30. Global NK Cell Therapy Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global NK Cell Therapy Revenue by Application (2021-2026) & (US$ Million) Table 32. Global NK Cell Therapy Revenue by Application (2027-2032) & (US$ Million) Table 33. Global NK Cell Therapy Revenue Market Share by Application (2021-2026) Table 34. Global NK Cell Therapy Revenue Market Share by Application (2027-2032) Table 35. Nektar Therapeutics Company Information Table 36. Nektar Therapeutics Business Overview Table 37. Nektar Therapeutics NK Cell Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Nektar Therapeutics NK Cell Therapy Product Portfolio Table 39. Nektar Therapeutics Recent Development Table 40. Innate Pharma SA Company Information Table 41. Innate Pharma SA Business Overview Table 42. Innate Pharma SA NK Cell Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Innate Pharma SA NK Cell Therapy Product Portfolio Table 44. Innate Pharma SA Recent Development Table 45. Affimed Company Information Table 46. Affimed Business Overview Table 47. Affimed NK Cell Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Affimed NK Cell Therapy Product Portfolio Table 49. Affimed Recent Development Table 50. Chipscreen Biosciences Company Information Table 51. Chipscreen Biosciences Business Overview Table 52. Chipscreen Biosciences NK Cell Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Chipscreen Biosciences NK Cell Therapy Product Portfolio Table 54. Chipscreen Biosciences Recent Development Table 55. Fate Therapeutics Company Information Table 56. Fate Therapeutics Business Overview Table 57. Fate Therapeutics NK Cell Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Fate Therapeutics NK Cell Therapy Product Portfolio Table 59. Fate Therapeutics Recent Development Table 60. Glycostem Therapeutics Company Information Table 61. Glycostem Therapeutics Business Overview Table 62. Glycostem Therapeutics NK Cell Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Glycostem Therapeutics NK Cell Therapy Product Portfolio Table 64. Glycostem Therapeutics Recent Development Table 65. Dragonfly Therapeutics Company Information Table 66. Dragonfly Therapeutics Business Overview Table 67. Dragonfly Therapeutics NK Cell Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Dragonfly Therapeutics NK Cell Therapy Product Portfolio Table 69. Dragonfly Therapeutics Recent Development Table 70. Kiadis Pharma Company Information Table 71. Kiadis Pharma Business Overview Table 72. Kiadis Pharma NK Cell Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Kiadis Pharma NK Cell Therapy Product Portfolio Table 74. Kiadis Pharma Recent Development Table 75. NantWorks Company Information Table 76. NantWorks Business Overview Table 77. NantWorks NK Cell Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. NantWorks NK Cell Therapy Product Portfolio Table 79. NantWorks Recent Development Table 80. Nkarta Therapeutics Company Information Table 81. Nkarta Therapeutics Business Overview Table 82. Nkarta Therapeutics NK Cell Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. Nkarta Therapeutics NK Cell Therapy Product Portfolio Table 84. Nkarta Therapeutics Recent Development Table 85. Fortress Biotech Company Information Table 86. Fortress Biotech Business Overview Table 87. Fortress Biotech NK Cell Therapy Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 88. Fortress Biotech NK Cell Therapy Product Portfolio Table 89. Fortress Biotech Recent Development Table 90. North America NK Cell Therapy Revenue by Type (2021-2026) & (US$ Million) Table 91. North America NK Cell Therapy Revenue by Type (2027-2032) & (US$ Million) Table 92. North America NK Cell Therapy Revenue by Application (2021-2026) & (US$ Million) Table 93. North America NK Cell Therapy Revenue by Application (2027-2032) & (US$ Million) Table 94. North America NK Cell Therapy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 95. North America NK Cell Therapy Revenue by Country (2021-2026) & (US$ Million) Table 96. North America NK Cell Therapy Revenue by Country (US$ Million) & (2027-2032) Table 97. Europe NK Cell Therapy Revenue by Type (2021-2026) & (US$ Million) Table 98. Europe NK Cell Therapy Revenue by Type (2027-2032) & (US$ Million) Table 99. Europe NK Cell Therapy Revenue by Application (2021-2026) & (US$ Million) Table 100. Europe NK Cell Therapy Revenue by Application (2027-2032) & (US$ Million) Table 101. Europe NK Cell Therapy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 102. Europe NK Cell Therapy Revenue by Country (2021-2026) & (US$ Million) Table 103. Europe NK Cell Therapy Revenue by Country (US$ Million) & (2027-2032) Table 104. China NK Cell Therapy Revenue by Type (2021-2026) & (US$ Million) Table 105. China NK Cell Therapy Revenue by Type (2027-2032) & (US$ Million) Table 106. China NK Cell Therapy Revenue by Application (2021-2026) & (US$ Million) Table 107. China NK Cell Therapy Revenue by Application (2027-2032) & (US$ Million) Table 108. Asia NK Cell Therapy Revenue by Type (2021-2026) & (US$ Million) Table 109. Asia NK Cell Therapy Revenue by Type (2027-2032) & (US$ Million) Table 110. Asia NK Cell Therapy Revenue by Application (2021-2026) & (US$ Million) Table 111. Asia NK Cell Therapy Revenue by Application (2027-2032) & (US$ Million) Table 112. Asia NK Cell Therapy Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 113. Asia NK Cell Therapy Revenue by Region (US$ Million) & (2021-2026) Table 114. Asia NK Cell Therapy Revenue by Region (US$ Million) & (2027-2032) Table 115. SAMEA NK Cell Therapy Revenue by Type (2021-2026) & (US$ Million) Table 116. SAMEA NK Cell Therapy Revenue by Type (2027-2032) & (US$ Million) Table 117. SAMEA NK Cell Therapy Revenue by Application (2021-2026) & (US$ Million) Table 118. SAMEA NK Cell Therapy Revenue by Application (2027-2032) & (US$ Million) Table 119. SAMEA NK Cell Therapy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 120. SAMEA NK Cell Therapy Revenue by Country (2021-2026) & (US$ Million) Table 121. SAMEA NK Cell Therapy Revenue by Country (US$ Million) & (2027-2032) Table 122. Research Programs/Design for This Report Table 123. Authors List of This Report Table 124. Secondary Sources Table 125. Primary Sources List of Figures Figure 1. NK Cell Therapy Image Figure 2. Global NK Cell Therapy Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global NK Cell Therapy Market Size Share 2021 VS 2025 VS 2032 Figure 4. NK Cell Therapies Image Figure 5. NK Cell Directed Antibodies Image Figure 6. Global NK Cell Therapy Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global NK Cell Therapy Market Size Share 2021 VS 2025 VS 2032 Figure 8. Cancer Image Figure 9. Gastrointestinal Diseases Image Figure 10. Others Image Figure 11. Global NK Cell Therapy Market Size (US$ Million) & (2021-2032) Figure 12. Global NK Cell Therapy Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global NK Cell Therapy Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global NK Cell Therapy Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global NK Cell Therapy Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global NK Cell Therapy Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global NK Cell Therapy Revenue Market Share by Type (2021-2032) Figure 19. Global NK Cell Therapy Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global NK Cell Therapy Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global NK Cell Therapy Revenue Market Share by Application (2021-2032) Figure 22. North America NK Cell Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America NK Cell Therapy Revenue Share by Type (2021-2032) Figure 24. North America NK Cell Therapy Revenue Share by Application (2021-2032) Figure 25. North America NK Cell Therapy Revenue Share by Country (2021-2032) Figure 26. United States NK Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada NK Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico NK Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe NK Cell Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe NK Cell Therapy Revenue Share by Type (2021-2032) Figure 31. Europe NK Cell Therapy Revenue Share by Application (2021-2032) Figure 32. Europe NK Cell Therapy Revenue Share by Country (2021-2032) Figure 33. Germany NK Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France NK Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. NK Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy NK Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain NK Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia NK Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands NK Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries NK Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China NK Cell Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China NK Cell Therapy Revenue Share by Type (2021-2032) Figure 43. China NK Cell Therapy Revenue Share by Application (2021-2032) Figure 44. Asia NK Cell Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia NK Cell Therapy Revenue Share by Type (2021-2032) Figure 46. Asia NK Cell Therapy Revenue Share by Application (2021-2032) Figure 47. Asia NK Cell Therapy Revenue Share by Region (2021-2032) Figure 48. Japan NK Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea NK Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India NK Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia NK Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan NK Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia NK Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA NK Cell Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA NK Cell Therapy Revenue Share by Type (2021-2032) Figure 56. SAMEA NK Cell Therapy Revenue Share by Application (2021-2032) Figure 57. SAMEA NK Cell Therapy Revenue Share by Country (2021-2032) Figure 58. Brazil NK Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina NK Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile NK Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia NK Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru NK Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia NK Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel NK Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE NK Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey NK Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran NK Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt NK Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • NK Cell Therapies
  • NK Cell Directed Antibodies
Applications
  • Cancer
  • Gastrointestinal Diseases
  • Others
Companies covered
  • Nektar Therapeutics
  • Innate Pharma SA
  • Affimed
  • Chipscreen Biosciences
  • Fate Therapeutics
  • Glycostem Therapeutics
  • Dragonfly Therapeutics
  • Kiadis Pharma
  • NantWorks
  • Nkarta Therapeutics
  • Fortress Biotech

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 NK Cell Therapy Market by Type
  3. 1.2.1 Global NK Cell Therapy Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 NK Cell Therapies
  5. 1.2.3 NK Cell Directed Antibodies
  6. 1.3 NK Cell Therapy Market by Application
  7. 1.3.1 Global NK Cell Therapy Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Cancer
  9. 1.3.3 Gastrointestinal Diseases
  10. 1.3.4 Others
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 NK Cell Therapy Market Dynamics
  1. 2.1 NK Cell Therapy Industry Trends
  2. 2.2 NK Cell Therapy Industry Drivers
  3. 2.3 NK Cell Therapy Industry Opportunities and Challenges
  4. 2.4 NK Cell Therapy Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global NK Cell Therapy Market Perspective (2021-2032)
  2. 3.2 Global NK Cell Therapy Growth Trends by Region
  3. 3.2.1 Global NK Cell Therapy Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global NK Cell Therapy Market Size by Region (2021-2026)
  5. 3.2.3 Global NK Cell Therapy Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global NK Cell Therapy Revenue by Players
  2. 4.1.1 Global NK Cell Therapy Revenue by Players (2021-2026)
  3. 4.1.2 Global NK Cell Therapy Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global NK Cell Therapy Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global NK Cell Therapy Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global NK Cell Therapy Key Players Headquarters & Area Served
  7. 4.4 Global NK Cell Therapy Players, Product Type & Application
  8. 4.5 Global NK Cell Therapy Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global NK Cell Therapy Market CR5 and HHI
  11. 4.6.3 2025 NK Cell Therapy Tier 1, Tier 2, and Tier 3
5 NK Cell Therapy Market Size by Type
  1. 5.1 Global NK Cell Therapy Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global NK Cell Therapy Revenue by Type (2021-2032)
  3. 5.3 Global NK Cell Therapy Revenue Market Share by Type (2021-2032)
6 NK Cell Therapy Market Size by Application
  1. 6.1 Global NK Cell Therapy Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global NK Cell Therapy Revenue by Application (2021-2032)
  3. 6.3 Global NK Cell Therapy Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Nektar Therapeutics
  2. 7.1.1 Nektar Therapeutics Company Information
  3. 7.1.2 Nektar Therapeutics Business Overview
  4. 7.1.3 Nektar Therapeutics NK Cell Therapy Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Nektar Therapeutics NK Cell Therapy Product Portfolio
  6. 7.1.5 Nektar Therapeutics Recent Developments
  7. 7.2 Innate Pharma SA
  8. 7.2.1 Innate Pharma SA Company Information
  9. 7.2.2 Innate Pharma SA Business Overview
  10. 7.2.3 Innate Pharma SA NK Cell Therapy Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Innate Pharma SA NK Cell Therapy Product Portfolio
  12. 7.2.5 Innate Pharma SA Recent Developments
  13. 7.3 Affimed
  14. 7.3.1 Affimed Company Information
  15. 7.3.2 Affimed Business Overview
  16. 7.3.3 Affimed NK Cell Therapy Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Affimed NK Cell Therapy Product Portfolio
  18. 7.3.5 Affimed Recent Developments
  19. 7.4 Chipscreen Biosciences
  20. 7.4.1 Chipscreen Biosciences Company Information
  21. 7.4.2 Chipscreen Biosciences Business Overview
  22. 7.4.3 Chipscreen Biosciences NK Cell Therapy Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Chipscreen Biosciences NK Cell Therapy Product Portfolio
  24. 7.4.5 Chipscreen Biosciences Recent Developments
  25. 7.5 Fate Therapeutics
  26. 7.5.1 Fate Therapeutics Company Information
  27. 7.5.2 Fate Therapeutics Business Overview
  28. 7.5.3 Fate Therapeutics NK Cell Therapy Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Fate Therapeutics NK Cell Therapy Product Portfolio
  30. 7.5.5 Fate Therapeutics Recent Developments
  31. 7.6 Glycostem Therapeutics
  32. 7.6.1 Glycostem Therapeutics Company Information
  33. 7.6.2 Glycostem Therapeutics Business Overview
  34. 7.6.3 Glycostem Therapeutics NK Cell Therapy Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Glycostem Therapeutics NK Cell Therapy Product Portfolio
  36. 7.6.5 Glycostem Therapeutics Recent Developments
  37. 7.7 Dragonfly Therapeutics
  38. 7.7.1 Dragonfly Therapeutics Company Information
  39. 7.7.2 Dragonfly Therapeutics Business Overview
  40. 7.7.3 Dragonfly Therapeutics NK Cell Therapy Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Dragonfly Therapeutics NK Cell Therapy Product Portfolio
  42. 7.7.5 Dragonfly Therapeutics Recent Developments
  43. 7.8 Kiadis Pharma
  44. 7.8.1 Kiadis Pharma Company Information
  45. 7.8.2 Kiadis Pharma Business Overview
  46. 7.8.3 Kiadis Pharma NK Cell Therapy Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Kiadis Pharma NK Cell Therapy Product Portfolio
  48. 7.8.5 Kiadis Pharma Recent Developments
  49. 7.9 NantWorks
  50. 7.9.1 NantWorks Company Information
  51. 7.9.2 NantWorks Business Overview
  52. 7.9.3 NantWorks NK Cell Therapy Revenue and Gross Margin (2021-2026)
  53. 7.9.4 NantWorks NK Cell Therapy Product Portfolio
  54. 7.9.5 NantWorks Recent Developments
  55. 7.10 Nkarta Therapeutics
  56. 7.10.1 Nkarta Therapeutics Company Information
  57. 7.10.2 Nkarta Therapeutics Business Overview
  58. 7.10.3 Nkarta Therapeutics NK Cell Therapy Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Nkarta Therapeutics NK Cell Therapy Product Portfolio
  60. 7.10.5 Nkarta Therapeutics Recent Developments
  61. 7.11 Fortress Biotech
  62. 7.11.1 Fortress Biotech Company Information
  63. 7.11.2 Fortress Biotech Business Overview
  64. 7.11.3 Fortress Biotech NK Cell Therapy Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Fortress Biotech NK Cell Therapy Product Portfolio
  66. 7.11.5 Fortress Biotech Recent Developments
8 North America
  1. 8.1 North America NK Cell Therapy Revenue (2021-2032)
  2. 8.2 North America NK Cell Therapy Revenue by Type (2021-2032)
  3. 8.2.1 North America NK Cell Therapy Revenue by Type (2021-2026)
  4. 8.2.2 North America NK Cell Therapy Revenue by Type (2027-2032)
  5. 8.3 North America NK Cell Therapy Revenue Share by Type (2021-2032)
  6. 8.4 North America NK Cell Therapy Revenue by Application (2021-2032)
  7. 8.4.1 North America NK Cell Therapy Revenue by Application (2021-2026)
  8. 8.4.2 North America NK Cell Therapy Revenue by Application (2027-2032)
  9. 8.5 North America NK Cell Therapy Revenue Share by Application (2021-2032)
  10. 8.6 North America NK Cell Therapy Revenue by Country
  11. 8.6.1 North America NK Cell Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America NK Cell Therapy Revenue by Country (2021-2026)
  13. 8.6.3 North America NK Cell Therapy Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe NK Cell Therapy Revenue (2021-2032)
  2. 9.2 Europe NK Cell Therapy Revenue by Type (2021-2032)
  3. 9.2.1 Europe NK Cell Therapy Revenue by Type (2021-2026)
  4. 9.2.2 Europe NK Cell Therapy Revenue by Type (2027-2032)
  5. 9.3 Europe NK Cell Therapy Revenue Share by Type (2021-2032)
  6. 9.4 Europe NK Cell Therapy Revenue by Application (2021-2032)
  7. 9.4.1 Europe NK Cell Therapy Revenue by Application (2021-2026)
  8. 9.4.2 Europe NK Cell Therapy Revenue by Application (2027-2032)
  9. 9.5 Europe NK Cell Therapy Revenue Share by Application (2021-2032)
  10. 9.6 Europe NK Cell Therapy Revenue by Country
  11. 9.6.1 Europe NK Cell Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe NK Cell Therapy Revenue by Country (2021-2026)
  13. 9.6.3 Europe NK Cell Therapy Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China NK Cell Therapy Revenue (2021-2032)
  2. 10.2 China NK Cell Therapy Revenue by Type (2021-2032)
  3. 10.2.1 China NK Cell Therapy Revenue by Type (2021-2026)
  4. 10.2.2 China NK Cell Therapy Revenue by Type (2027-2032)
  5. 10.3 China NK Cell Therapy Revenue Share by Type (2021-2032)
  6. 10.4 China NK Cell Therapy Revenue by Application (2021-2032)
  7. 10.4.1 China NK Cell Therapy Revenue by Application (2021-2026)
  8. 10.4.2 China NK Cell Therapy Revenue by Application (2027-2032)
  9. 10.5 China NK Cell Therapy Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia NK Cell Therapy Revenue (2021-2032)
  2. 11.2 Asia NK Cell Therapy Revenue by Type (2021-2032)
  3. 11.2.1 Asia NK Cell Therapy Revenue by Type (2021-2026)
  4. 11.2.2 Asia NK Cell Therapy Revenue by Type (2027-2032)
  5. 11.3 Asia NK Cell Therapy Revenue Share by Type (2021-2032)
  6. 11.4 Asia NK Cell Therapy Revenue by Application (2021-2032)
  7. 11.4.1 Asia NK Cell Therapy Revenue by Application (2021-2026)
  8. 11.4.2 Asia NK Cell Therapy Revenue by Application (2027-2032)
  9. 11.5 Asia NK Cell Therapy Revenue Share by Application (2021-2032)
  10. 11.6 Asia NK Cell Therapy Revenue by Country
  11. 11.6.1 Asia NK Cell Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia NK Cell Therapy Revenue by Country (2021-2026)
  13. 11.6.3 Asia NK Cell Therapy Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA NK Cell Therapy Revenue (2021-2032)
  2. 12.2 SAMEA NK Cell Therapy Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA NK Cell Therapy Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA NK Cell Therapy Revenue by Type (2027-2032)
  5. 12.3 SAMEA NK Cell Therapy Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA NK Cell Therapy Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA NK Cell Therapy Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA NK Cell Therapy Revenue by Application (2027-2032)
  9. 12.5 SAMEA NK Cell Therapy Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA NK Cell Therapy Revenue by Country
  11. 12.6.1 SAMEA NK Cell Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA NK Cell Therapy Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA NK Cell Therapy Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst